ALX ONCOLOGY HOLDINGS INC Income (Loss) from Continuing Operations before Income Taxes, Domestic
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$101.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-09
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$101.20M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$134.12M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$159.77M.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$111.36M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$101.20M 10-K · filed 2026-03-09 | |
| 2024-12-31 | -$134.12M 10-K · filed 2026-03-09 | |
| 2023-12-31 | -$159.77M 10-K · filed 2026-03-09 | |
| 2022-12-31 | -$111.36M 10-K · filed 2025-03-06 | |
| 2021-12-31 | -$30.57M 10-K · filed 2024-03-07 | -$52.92M 10-K · filed 2022-02-28 |
| 2020-12-31 | -$9.46M 10-K · filed 2023-03-09 | -$36.04M 10-K · filed 2021-03-18 |
| 2019-12-31 | -$20.02M 10-K · filed 2022-02-28 | |
| 2018-12-31 | -$14.54M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |